AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28622959 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of panobinostat and lenalidomide
Number of subjects: 24
Study 28623183 — intervention group
Group type: EXPERIMENTAL
Intervention: EpxDepression
Number of subjects: 9
Study 28623183 — intervention group
Group type: EXPERIMENTAL
Intervention: EpxAutism
Number of subjects: 9
Study 28623185 — intervention group
Group type: EXPERIMENTAL
Intervention: iENGAGE behavioral health intervention
Number of subjects: 13
Study 28623186 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted versions of the Wii Fit balance board and gaming mat
Number of subjects: 0
Study 28623186 — intervention group
Group type: COMPARATOR
Intervention: Off-the-shelf versions of the Wii Fit balance board and gaming mat
Number of subjects: 0
Study 28623539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy (TBB) during research bronchoscopy
Number of subjects: 97
Study 28623902 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of atherogenic dyslipidemia (elevated triglyceride levels and low levels of high-density lipoprotein cholesterol)
Number of subjects: 7641
Study 28623902 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpopulations with type 2 diabetes mellitus or high cardiovascular disease risk
Number of subjects: 7641
Study 28623902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 7641
Study 28623902 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal treatment as specified in international guidelines
Number of subjects: 7641
Study 28623988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/d) for EHIT prophylaxis
Number of subjects: 306
Study 28623992 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence lymphatic imaging
Number of subjects: 1
Study 28623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment approaches for SVT (including oral and injectable anticoagulants, pain medication, compression therapy, and no treatment)
Number of subjects: 1200
Study 28623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires (VEINES-QOL/Sym, EQ-5D-5L)
Number of subjects: 1200
Study 28623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of venous thromboembolism
Number of subjects: 1200
Study 28623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined incidence of major and clinically relevant bleeding events
Number of subjects: 1200
Study 28624396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET) with late gadolinium enhancement (LGE) and FDG
Number of subjects: 25
Study 28624396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET)
Number of subjects: 25
Study 28624388 — intervention group
Group type: EXPERIMENTAL
Intervention: European high-income countries (Europe-High)
Number of subjects: 2813
Study 28624388 — intervention group
Group type: EXPERIMENTAL
Intervention: High-income countries in the rest of the world (rWORLD-High)
Number of subjects: 2813
Study 28624388 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-income countries (Middle)
Number of subjects: 2813
Study 28624388 — intervention group
Group type: EXPERIMENTAL
Intervention: Income per person
Number of subjects: 2813
Study 28624608 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels
Number of subjects: 652
Study 28624608 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil counts
Number of subjects: 652
Study 28624608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction of exhaled nitric oxide values
Number of subjects: 652
Study 28624608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum eosinophil counts
Number of subjects: 652
Study 28624664 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-thickness excision of bladder endometriosis nodule (70%)
Number of subjects: 81
Study 28624664 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of bladder wall without opening of bladder (30%)
Number of subjects: 81
Study 28624664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureterolysis (78%)
Number of subjects: 81
Study 28624664 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary segmental resection (22%)
Number of subjects: 81
Study 28624664 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management of urinary tract endometriosis
Number of subjects: 81
Study 28624860 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight group (BMI < 25)
Number of subjects: 46
Study 28624860 — intervention group
Group type: COMPARATOR
Intervention: Obese group (BMI > 30)
Number of subjects: 46
Study 28625365 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28625380 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (including dabigatran, rivaroxaban, apixaban)
Number of subjects: 4670
Study 28625380 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4670
Study 28625502 — intervention group
Group type: EXPERIMENTAL
Intervention: Computable phenotype
Number of subjects: 413
Study 28625502 — intervention group
Group type: COMPARATOR
Intervention: Registry
Number of subjects: 413
Study 28625503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/day
Number of subjects: 8
Study 28625579 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte Distribution Width (MDW)
Number of subjects: 1320
Study 28625579 — intervention group
Group type: EXPERIMENTAL
Intervention: MDW + WBC count
Number of subjects: 1320
Study 28625629 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 30mg and sirolimus 1mg
Number of subjects: 39
Study 28625629 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib and sirolimus
Number of subjects: 39
Study 28625777 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (Herceptin) 600 mg fixed-dose every 3 weeks for 18 cycles
Number of subjects: 2573
Study 28625816 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 22
Study 28625816 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 22
Study 28625834 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell activity test
Number of subjects: 872
Study 28625964 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade dissection and reentry (ADR)
Number of subjects: 292
Study 28625964 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ADR (combined CrossBoss-Stingray)
Number of subjects: 292
Study 28626781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (3.5 mg/kg; 5.25 mg/kg)
Number of subjects: 0
Study 28626781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (3.5 mg/kg)
Number of subjects: 0
Study 28626781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 0
Study 28629333 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5-month fluoroquinolone-containing regimen (levofloxacin, isoniazid, rifampin, parazinamid, ethambutol)
Number of subjects: 0
Study 28629333 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5-month regimen (isoniazid, rifampin, parazinamid, ethambutol without levofloxacin)
Number of subjects: 0
Study 28629333 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 months of isoniazid, rifampin, parazinamid, ethambutol followed by 4 months of isoniazid and rifampin)
Number of subjects: 0
Study 28629348 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-mail fecal immunochemical testing (FIT) program
Number of subjects: 0
Study 28629348 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSA process
Number of subjects: 0
Study 28629390 — intervention group
Group type: EXPERIMENTAL
Intervention: REX powered walking aid
Number of subjects: 20
Study 28629395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) therapy initiated based on EASL criteria; 74 patients (24.7%) started TDF therapy, 46 (62.2%) had cirrhosis.
Number of subjects: 300
Study 28629437 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoSyp programmed to deliver magnesium sulfate (MgSO4) intravenously
Number of subjects: 22
Study 28629466 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction (SVF) and platelet rich plasma (PRP) intra-articular injection
Number of subjects: 10
Study 28629584 — intervention group
Group type: EXPERIMENTAL
Intervention: Met the vitamin D estimated average requirement (EAR) intake (10 μg/d)
Number of subjects: 132
Study 28629584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient serum 25-hydroxyvitamin D (25(OH)D) (≥50 nmol/L)
Number of subjects: 132
Study 28629584 — intervention group
Group type: COMPARATOR
Intervention: Did not meet the vitamin D EAR
Number of subjects: 132
Study 28629584 — intervention group
Group type: COMPARATOR
Intervention: Serum levels at risk for inadequacy or deficiency (<50 nmol/L)
Number of subjects: 132
Study 28630037 — intervention group
Group type: EXPERIMENTAL
Intervention: bant app plus usual care
Number of subjects: 92
Study 28630037 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 92
Study 28630120 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 0
Study 28630120 — intervention group
Group type: COMPARATOR
Intervention: TPO agonists
Number of subjects: 0
Study 28630121 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO) therapy
Number of subjects: 0
Study 28630189 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 0
Study 28630212 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT) combined with Cytoreductive Nephrectomy
Number of subjects: 0
Study 28630212 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28630876 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT with doses of 69Gy, 75Gy, and 81Gy in 30 fractions to the internal gross tumor volume (iGTV)
Number of subjects: 20
Study 28630876 — intervention group
Group type: COMPARATOR
Intervention: Standard IMRT plans prescribed a dose of 60Gy to the planning tumor volume (PTV)
Number of subjects: 20
Study 28631088 — intervention group
Group type: EXPERIMENTAL
Intervention: ARDS patients with no identified risk factors
Number of subjects: 234
Study 28631088 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 234
Study 28631088 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung biopsy
Number of subjects: 234
Study 28631088 — intervention group
Group type: EXPERIMENTAL
Intervention: Left heart filling pressures assessment
Number of subjects: 234
Study 28631088 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific diagnosis made
Number of subjects: 234
Study 28631283 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 417
Study 28631283 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) and having both parents living together
Number of subjects: 417
Study 28632462 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Integrated Cognitive-Behavioral Therapy (ICBT)
Number of subjects: 123
Study 28633365 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 84
Study 28633365 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib
Number of subjects: 84
Study 28633375 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with a self-expanding bioprosthesis
Number of subjects: 1015
Study 28633425 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 97
Study 28633478 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D transoesophageal echocardiography-derived formula for device size determination without balloon sizing
Number of subjects: 248
Study 28633478 — intervention group
Group type: COMPARATOR
Intervention: 3D transoesophageal echocardiography-derived formula for device size determination with balloon sizing
Number of subjects: 248
Study 28634491 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily growth hormone treatment (group A, 16 patients)
Number of subjects: 32
Study 28634491 — intervention group
Group type: COMPARATOR
Intervention: Three-times-weekly growth hormone treatment (group B, 16 patients)
Number of subjects: 32
Study 28636901 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34
Number of subjects: 0
Study 28637445 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard local practice treatment for posterior fossa tumours
Number of subjects: 500
Study 28637445 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized surgical data
Number of subjects: 500
Study 28637445 — intervention group
Group type: EXPERIMENTAL
Intervention: Other therapeutic interventions
Number of subjects: 500
Study 28637445 — intervention group
Group type: EXPERIMENTAL
Intervention: Host genome variants
Number of subjects: 500
Study 28637514 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-INR measurement using Coagucheck® XS Pro device
Number of subjects: 98
Study 28637514 — intervention group
Group type: COMPARATOR
Intervention: lab-INR measurement on plasma
Number of subjects: 98
Study 28637631 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Food Photography Method (RFPM)
Number of subjects: 54
Study 28637662 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus pomalidomide and dexamethasone (pom-dex)
Number of subjects: 103
Study 28637772 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased supplemented dietary intakes of methionine
Number of subjects: 0
Study 28637923 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria sporozoites
Number of subjects: 0
Study 28637923 — intervention group
Group type: COMPARATOR
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 0
Study 28638328 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with intravenous infusion of propofol and maintenance with isoflurane for 3 hours
Number of subjects: 60
Study 28638328 — intervention group
Group type: COMPARATOR
Intervention: Awake controls
Number of subjects: 60
Study 28639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin
Number of subjects: 2585
Study 28639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPIs)
Number of subjects: 2585
Study 28639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2585
Study 28639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 2585
Study 28639987 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 2585
Study 28639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 2585
Study 28639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin, GPIs, bivalirudin
Number of subjects: 2585
Study 28640364 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 50
Study 28641783 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of T1D women (index offspring)
Number of subjects: 568
Study 28641783 — intervention group
Group type: COMPARATOR
Intervention: Control offspring
Number of subjects: 568
Study 28642288 — intervention group
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Number of subjects: 31
Study 28642288 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 31
Study 28642315 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide, dosage and duration not available
Number of subjects: 0
Study 28642620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (1-4 mg days 1-14), bortezomib (1-1.3 mg/m2), low-dose dexamethasone (LoDEX)
Number of subjects: 0
Study 28642620 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (subcutaneous (SC) or intravenous (IV))
Number of subjects: 0
Study 28642620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (LoDEX)
Number of subjects: 0
Study 28642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory allogeneic dendritic cells (DCs)
Number of subjects: 12
Study 28642820 — intervention group
Group type: COMPARATOR
Intervention: Standard tyrosine kinase inhibitors (TKI)
Number of subjects: 12
Study 28642891 — intervention group
Group type: EXPERIMENTAL
Intervention: VX15/2503 (1, 3, 6, 10, or 20 mg/kg)
Number of subjects: 50
Study 28642891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28642891 — intervention group
Group type: EXPERIMENTAL
Intervention: VX15/2503
Number of subjects: 50
Study 28643171 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-force (CF) sensing technology with radiofrequency energy ablation, targeting at least 10g (ideally 20g) of force, with the endpoint of eliminating the negative component of the unipolar atrial signal.
Number of subjects: 215
Study 28643214 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Lotus Valve
Number of subjects: 400
Study 28643214 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien S3
Number of subjects: 400
Study 28643214 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien XT
Number of subjects: 400
Study 28643214 — intervention group
Group type: COMPARATOR
Intervention: Medtronic CoreValve
Number of subjects: 400
Study 28643214 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation devices (Boston Lotus and Edwards Sapien 3)
Number of subjects: 400
Study 28643214 — intervention group
Group type: COMPARATOR
Intervention: Last generation devices (Medtronic CoreValve and Edwards Sapien XT)
Number of subjects: 400
Study 28643275 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of nitisinone
Number of subjects: 19
Study 28643275 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dosing of nitisinone
Number of subjects: 19
Study 28644056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticles (NANOM)
Number of subjects: 180
Study 28644056 — intervention group
Group type: COMPARATOR
Intervention: Ferro
Number of subjects: 180
Study 28644056 — intervention group
Group type: COMPARATOR
Intervention: Stenting (XIENCE V)
Number of subjects: 180
Study 28644099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous irrigation and drainage (CID)
Number of subjects: 1260
Study 28644099 — intervention group
Group type: COMPARATOR
Intervention: Passive subdural drainage (PD)
Number of subjects: 1260
Study 28644099 — intervention group
Group type: COMPARATOR
Intervention: Active subgaleal drainage (AD)
Number of subjects: 1260
Study 28644367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholic acid (10 to 15 mg·kg·day)
Number of subjects: 85
Study 28644602 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic repair
Number of subjects: 228
Study 28644602 — intervention group
Group type: COMPARATOR
Intervention: Conventional open aortic surgery
Number of subjects: 228
Study 28644602 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic aortic surgery
Number of subjects: 228
Study 28644602 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 228
Study 28645324 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Guidelines (PAGs) compliance
Number of subjects: 419
Study 28645324 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA) measured with SenseWear™ armband
Number of subjects: 419
Study 28645324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity recommendation
Number of subjects: 419
Study 28645324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time reduction recommendation
Number of subjects: 419
Study 28645776 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (oral, once daily) at various doses (20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg)
Number of subjects: 252
Study 28645776 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (oral, once daily) at various doses
Number of subjects: 252
Study 28645776 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (oral, once daily)
Number of subjects: 252
Study 28645867 — intervention group
Group type: COMPARATOR
Intervention: Pressure pain tolerance
Number of subjects: 18
Study 28645867 — intervention group
Group type: COMPARATOR
Intervention: Pain ratings to repetitive suprathreshold electrical stimulation (SES)
Number of subjects: 18
Study 28645867 — intervention group
Group type: COMPARATOR
Intervention: Conditioned pain modulation (CPM)
Number of subjects: 18
Study 28645867 — intervention group
Group type: COMPARATOR
Intervention: Event-related potentials (ERPs) in response to repetitive SES
Number of subjects: 18
Study 28645891 — intervention group
Group type: EXPERIMENTAL
Intervention: Health apps (various types including exercise, fitness, diet, and mental health apps)
Number of subjects: 176
Study 28645891 — intervention group
Group type: EXPERIMENTAL
Intervention: Health apps (various types)
Number of subjects: 176
Study 28645891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health apps
Number of subjects: 176
Study 28645937 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended treatments for ST-elevation myocardial infarction
Number of subjects: 12108
Study 28645937 — intervention group
Group type: EXPERIMENTAL
Intervention: Defect-free rate of guideline-recommended treatments
Number of subjects: 12108
Study 28645937 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-standardized mortality rates
Number of subjects: 12108
Study 28645967 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite blood-based biomarker
Number of subjects: 600
Study 28645967 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite electronic smartphone-based biomarker
Number of subjects: 600
Study 28645967 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive and neuroimaging-based signature
Number of subjects: 600
Study 28646344 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy A+B (after biomarker information)
Number of subjects: 439
Study 28646344 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy A alone (without biomarker information)
Number of subjects: 439
Study 28646344 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician recommendations (after biomarker information)
Number of subjects: 439
Study 28646344 — intervention group
Group type: COMPARATOR
Intervention: Physician recommendations (without biomarker information)
Number of subjects: 439